# Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

> **NCT00756249** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 16 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Lu AA24493 (CEPO)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00756249
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-09
- **Final completion:** 2008-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2010-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00756249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00756249, "Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00756249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*